SCD

bluebird bio, Inc. (BLUE) Class Action Notice: Robbins LLP Reminds Stockholders of Lead Plaintiff Deadline in Class Action Against bluebird bio, Inc.

Retrieved on: 
Tuesday, April 9, 2024
Sickle cell disease, Biotechnology, Bluebird, Clinical, DSM-IV codes, Patient, History, News, LLP, Cancer, Commercial, Complaint, BLUE, File, SCD, Bluebird bio, FDA, BLA, Food, Person, Pharmaceutical industry

Bluebird is a biotechnology company that researches, develops, and commercializes gene therapies for severe genetic diseases.

Key Points: 
  • Bluebird is a biotechnology company that researches, develops, and commercializes gene therapies for severe genetic diseases.
  • For more information, submit a form , email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003.
  • A lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation.
  • If you choose to take no action, you can remain an absent class member.

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Blue, and Luna Innovations and Encourages Investors to Contact the Firm

Retrieved on: 
Saturday, April 6, 2024
Sickle cell disease, Biotechnology, Luna Innovations, Bluebird, Blue, DSM-IV codes, Patient, Defendant, History, News, Cancer, Bank statement, False, Complaint, P.C, Elivaldogene autotemcel, File, SCD, FDA, BLA, Food

Stockholders have until the deadlines below to petition the court to serve as lead plaintiff.

Key Points: 
  • Stockholders have until the deadlines below to petition the court to serve as lead plaintiff.
  • Blue is a biotechnology company that researches, develops, and commercializes gene therapies for severe genetic diseases.
  • According to the complaint, the Company’s announcement provided investors with false and misleading information in order to bolster investor expectations and share prices.
  • For more information on the Luna Innovations class action go to: https://bespc.com/cases/LUNA

BLUE INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that bluebird bio, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

Retrieved on: 
Friday, April 5, 2024
Sickle cell disease, Biotechnology, Blue, DSM-IV codes, Patient, History, Class, News, Cancer, Complaint, File, SCD, FDA, BLA, Court, Bluebird bio, Food, Person, Pharmaceutical industry

According to the Complaint, Blue is a biotechnology company that researches, develops, and commercializes gene therapies for severe genetic diseases.

Key Points: 
  • According to the Complaint, Blue is a biotechnology company that researches, develops, and commercializes gene therapies for severe genetic diseases.
  • or his Law Clerk and Client Relations Manager, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC at 332-239-2660.
  • If you suffered a loss in Blue you have until May 28, 2024, to request that the Court appoint you as lead plaintiff.
  • Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits.

Aggreko Named the Official Military Appreciation Partner of THE CJ CUP Byron Nelson on PGA TOUR

Retrieved on: 
Tuesday, April 2, 2024
Temperature, Ryder Cup, HOPE, Veteran, Heat, Official, Military personnel, Workforce, SCD, TPC Craig Ranch, PGA, Golf, Tourism

Aggreko is working with the Salesmanship Club of Dallas (SCD) , which hosts THE CJ CUP Byron Nelson , to sponsor the prestigious golf tournament as the Official Military Appreciation Partner.

Key Points: 
  • Aggreko is working with the Salesmanship Club of Dallas (SCD) , which hosts THE CJ CUP Byron Nelson , to sponsor the prestigious golf tournament as the Official Military Appreciation Partner.
  • As the Military Partner, Aggeko’s support will enable all active duty, reserve, retired, and veteran military personnel, as well as national guard, to receive two complimentary tickets per day to THE CJ CUP Byron Nelson.
  • Military attendees of THE CJ CUP Byron Nelson will also be able to enjoy the Military Outpost, a dedicated hospitality tent located at the 7th tee.
  • Members of the military can visit the tournament’s website to register for their complimentary tickets to THE CJ CUP Byron Nelson.

BLUE INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that bluebird bio, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

Retrieved on: 
Monday, April 1, 2024
Sickle cell disease, Biotechnology, Blue, DSM-IV codes, Patient, History, Class, News, Cancer, Complaint, File, SCD, FDA, BLA, Court, Bluebird bio, Food, Person, Pharmaceutical industry

According to the Complaint, Blue is a biotechnology company that researches, develops, and commercializes gene therapies for severe genetic diseases.

Key Points: 
  • According to the Complaint, Blue is a biotechnology company that researches, develops, and commercializes gene therapies for severe genetic diseases.
  • or his Law Clerk and Client Relations Manager, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC at 332-239-2660.
  • If you suffered a loss in Blue you have until May 28, 2024, to request that the Court appoint you as lead plaintiff.
  • Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits.

Investor Notice: Robbins LLP Informs Investors of Class Action Filed Against bluebird bio, Inc. (BLUE)

Retrieved on: 
Saturday, March 30, 2024
Sickle cell disease, Biotechnology, Bluebird, Clinical, SAN, DSM-IV codes, Patient, History, News, LLP, Cancer, Commercial, Complaint, BLUE, File, SCD, FDA, BLA, Bluebird bio, Food, Person, Pharmaceutical industry

SAN DIEGO, March 30, 2024 (GLOBE NEWSWIRE) -- Robbins LLP informs investors that a shareholder filed a class action on behalf of all persons and entities that purchased or otherwise acquired bluebird bio, Inc. (NASDAQ: BLUE) common stock between April 24, 2023 and December 8, 2023.

Key Points: 
  • SAN DIEGO, March 30, 2024 (GLOBE NEWSWIRE) -- Robbins LLP informs investors that a shareholder filed a class action on behalf of all persons and entities that purchased or otherwise acquired bluebird bio, Inc. (NASDAQ: BLUE) common stock between April 24, 2023 and December 8, 2023.
  • Bluebird is a biotechnology company that researches, develops, and commercializes gene therapies for severe genetic diseases.
  • For more information, submit a form , email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003.
  • A lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation.

BLUE INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that bluebird bio, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

Retrieved on: 
Saturday, March 30, 2024
Sickle cell disease, Biotechnology, Bluebird bio, SAN, DSM-IV codes, Patient, History, News, Cancer, Complaint, SCD, Bluebird, Food, FDA, BLA, Pharmaceutical industry

), the bluebird bio class action lawsuit charges bluebird bio and certain of bluebird bio’s top executives with violations of the Securities Exchange Act of 1934.

Key Points: 
  • ), the bluebird bio class action lawsuit charges bluebird bio and certain of bluebird bio’s top executives with violations of the Securities Exchange Act of 1934.
  • A lead plaintiff acts on behalf of all other class members in directing the bluebird bio class action lawsuit.
  • The lead plaintiff can select a law firm of its choice to litigate the bluebird bio class action lawsuit.
  • An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff of the bluebird bio class action lawsuit.

BLUE ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Bluebird bio Inc. and Encourages Investors to Contact the Firm

Retrieved on: 
Friday, March 29, 2024
Sickle cell disease, Biotechnology, Telephone, Blue, District court, DSM-IV codes, Defendant, Patient, History, News, Cancer, False, Complaint, P.C, Elivaldogene autotemcel, SCD, File, FDA, BLA, Court, Food, Person

Investors have until May 27, 2024 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

Key Points: 
  • Investors have until May 27, 2024 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
  • Click here to participate in the action.
  • Blue is a biotechnology company that researches, develops, and commercializes gene therapies for severe genetic diseases.
  • According to the complaint, the Company’s announcement provided investors with false and misleading information in order to bolster investor expectations and share prices.

BLUE INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that bluebird bio, Inc. Investors with Substantial Losses Have Opportunity to Lead the bluebird bio Class Action Lawsuit

Retrieved on: 
Thursday, March 28, 2024
Sickle cell disease, Biotechnology, Bluebird bio, SAN, DSM-IV codes, Patient, History, News, Cancer, Complaint, SCD, Bluebird, Food, FDA, BLA, Pharmaceutical industry

), the bluebird bio class action lawsuit charges bluebird bio and certain of bluebird bio’s top executives with violations of the Securities Exchange Act of 1934.

Key Points: 
  • ), the bluebird bio class action lawsuit charges bluebird bio and certain of bluebird bio’s top executives with violations of the Securities Exchange Act of 1934.
  • A lead plaintiff acts on behalf of all other class members in directing the bluebird bio class action lawsuit.
  • The lead plaintiff can select a law firm of its choice to litigate the bluebird bio class action lawsuit.
  • An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff of the bluebird bio class action lawsuit.

BLUE INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that bluebird bio, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

Retrieved on: 
Tuesday, April 9, 2024
Class Action Lawsuit, Professional Services, Legal, Sickle cell disease, Biotechnology, Bluebird bio, DSM-IV codes, Patient, History, News, Cancer, Complaint, SCD, Bluebird, Food, FDA, BLA, Tobacco

), the bluebird bio class action lawsuit charges bluebird bio as well as certain of bluebird bio’s top executives with violations of the Securities Exchange Act of 1934.

Key Points: 
  • ), the bluebird bio class action lawsuit charges bluebird bio as well as certain of bluebird bio’s top executives with violations of the Securities Exchange Act of 1934.
  • A lead plaintiff acts on behalf of all other class members in directing the bluebird bio class action lawsuit.
  • The lead plaintiff can select a law firm of its choice to litigate the bluebird bio class action lawsuit.
  • An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff of the bluebird bio class action lawsuit.